medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2021, Número 1

<< Anterior Siguiente >>

Medicina & Laboratorio 2021; 25 (1)


Ginecomastia: aspectos generales y etiológicos

Bonilla-Sepúlveda OA

Idioma: Español
Referencias bibliográficas: 67
Paginas: 393-408
Archivo PDF: 143.71 Kb.


RESUMEN

La ginecomastia es el crecimiento mamario benigno en el varón. Etiológicamente se clasifica en fisiológica y patológica. La ginecomastia fisiológica se presenta frecuentemente en ciertos periodos de la vida, como la época neonatal, puberal y senil. La patológica se asocia a múltiples factores, incluyendo los hormonales, los de origen tumoral, y al uso de ciertos medicamentos, entre otros; sin embargo, en muchos pacientes no se consigue identificar nunca la causa. La historia clínica y el examen físico son los pilares fundamentales que permiten orientar hacia la etiología, con el apoyo de pruebas de laboratorio e imagenología que permitan descartar una enfermedad clínica subyacente. En los casos moderados o severos, la cirugía es el tratamiento de elección. El objetivo del presente manuscrito es discutir algunos puntos de interés acerca de los aspectos más importantes relacionados con la ginecomastia, incluyendo la fisiopatología, la clínica y el diagnóstico, además de presentar las principales causas asociadas a esta condición. Por último, se describen los tipos de tratamiento disponibles para estos pacientes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Vandeven HA, Pensler JM. Gynecomastia.Treasure Island (FL): StatPearls Publishing; 2020. Acceso 7 de octubre de 2020. Disponibleen https://www.ncbi.nlm.nih.gov/books/NBK430812/.

  2. Narula HS, Carlson HE. Gynecomastia. EndocrinolMetab Clin North Am 2007;36:497-519.https://doi.org/10.1016/j.ecl.2007.03.013.

  3. Costanzo PR, Pacenza NA, Aszpis SM, SuárezSM, Pragier UM, Usher JGS, et al. Clinicaland etiological aspects of gynecomastiain adult males: A multicenter study. BiomedRes Int 2018;2018:8364824. https://doi.org/10.1155/2018/8364824.

  4. Costanzo P, Suarez S, Aszpis S, Usher JG, PragierU, Cayoja M, et al. Ginecomastia: aspectosclínicos y etiológicos. Estudio retrospectivoy multicéntrico. Rev Argent Endocrinol Metab2015;52:22-28.

  5. Barrantes-Rodríguez K. Ginecomastia: manifestaciones,etiología, abordaje diagnóstico y tratamiento.Med Leg Costa Rica 2016;33:205-210.

  6. Nuttall FQ. Gynecomastia as a physical findingin normal men. J Clin Endocrinol Metab1979;48:338-340. https://doi.org/10.1210/jcem-48-2-338.

  7. Carlson HE. Gynecomastia. N Engl J Med1980;303:795-799. https://doi.org/10.1056/nejm198010023031405.

  8. Nydick M, Bustos J, Dale JH, Jr., RawsonRW. Gynecomastia in adolescent boys. Jama1961;178:449-454. https://doi.org/10.1001/jama.1961.03040440001001.

  9. Kanakis GA, Nordkap L, Bang AK, CalogeroAE, Bártfai G, Corona G, et al. EAA clinical practiceguidelines-gynecomastia evaluation and management.Andrology 2019;7:778-793. https://doi.org/10.1111/andr.12636.

  10. Braunstein GD. Clinical practice. Gynecomastia.N Engl J Med 2007;357:1229-1237. https://doi.org/10.1056/NEJMcp070677.

  11. Lorek M, Tobolska-Lorek D, Kalina-Faska B,Januszek-Trzciakowska A, Gawlik A. Clinicaland biochemical phenotype of adolescent maleswith gynecomastia. J Clin Res Pediatr Endocrinol2019;11:388-394. https://doi.org/10.4274/jcrpe.galenos.2019.2019.0027.

  12. Sansone A, Romanelli F, Sansone M, Lenzi A, DiLuigi L. Gynecomastia and hormones. Endocrine2017;55:37-44. https://doi.org/10.1007/s12020-016-0975-9.

  13. Narula HS, Carlson HE. Gynaecomastia--pathophysiology, diagnosis and treatment. NatRev Endocrinol 2014;10:684-698. https://doi.org/10.1038/nrendo.2014.139.

  14. Karagiannis A, Harsoulis F. Gonadal dysfunctionin systemic diseases. Eur J Endocrinol2005;152:501-513. https://doi.org/10.1530/eje.1.01886.

  15. Fricke A, Lehner GM, Stark GB, Penna V.Gynecomastia: histological appearance in differentage groups. J Plast Surg Hand Surg2018;52:166-171. https://doi.org/10.1080/2000656x.2017.1372291.

  16. Calderón OW, Cabello PR, Israel VG, BassaSJ, Kauak KL, Olguín MF, et al. Ginecomastiay pseudoginecomastia: Tratamiento. Rev Chil Cir2009;61:131-135.

  17. Einav-Bachar R, Phillip M, Aurbach-KlipperY, Lazar L. Prepubertal gynaecomastia: aetiology,course and outcome. Clin Endocrinol (Oxf)2004;61:55-60. https://doi.org/10.1111/j.1365-2265.2004.02059.x.

  18. Mieritz MG, Rakêt LL, Hagen CP, Nielsen JE,Talman LM, Petersen JH, et al. A longitudinalstudy of growth, sex steroids, and IGF-1 in boyswith physiological gynecomastia. J Clin EndocrinolMetab 2015;100:3752-3759. https://doi.org/10.1210/jc.2015-2836.

  19. Morcos RN, Kizy T. Gynecomastia: when istreatment indicated? J Fam Pract 2012;61:719-725.

  20. Krysiak R, Okopień B. [Gynecomastia]. PolMerkur Lekarski 2012;32:187-193.

  21. Haynes BA, Mookadam F. Male gynecomastia.Mayo Clin Proc 2009;84:672-672. https://doi.org/10.1016/S0025-6196(11)60515-6.

  22. Cakan N, Kamat D. Gynecomastia: evaluationand treatment recommendations for primary careproviders. Clin Pediatr (Phila) 2007;46:487-490.https://doi.org/10.1177/0009922806294800.

  23. Braunstein GD. Environmental gynecomastia.Endocr Pract 2008;14:409-411. https://doi.org/10.4158/ep.14.4.409.

  24. Rosenfeld VR. Andropausia o deficiencia androgénicadel adulto mayor. Rev Med Clin Cond2009;20:161-165.

  25. Montes JM. Andropausia o HIT – Diagnóstico ytratamiento del déficit de testosterona. Medicina2010;5:53-65.

  26. Zirkin BR, Tenover JL. Aging and declining testosterone:past, present, and hopes for the future.J Andrology 2012;33:1111-1118. https://doi.org/10.2164/jandrol.112.017160.

  27. Thompson DF, Carter JR. Drug-induced gynecomastia.Pharmacotherapy 1993;13:37-45.https://doi.org/10.1002/j.1875-9114.1993.tb02688.x.

  28. Ismail AA, Barth JH. Endocrinology of gynaecomastia.Ann Clin Biochem 2001;38:596-607.https://doi.org/10.1258/0004563011900993.

  29. Mathur R, Braunstein GD. Gynecomastia:pathomechanisms and treatment strategies.Horm Res 1997;48:95-102. https://doi.org/10.1159/000185497.

  30. Mieritz MG, Christiansen P, Jensen MB, JoensenUN, Nordkap L, Olesen IA, et al. Gynaecomastiain 786 adult men: clinical and biochemicalfindings. Eur J Endocrinol 2017;176:555-566.https://doi.org/10.1530/eje-16-0643.

  31. Ford HC, Cooke RR, Keightley EA, FeekCM. Serum levels of free and bound testosteronein hyperthyroidism. Clin Endocrinol(Oxf) 1992;36:187-192. https://doi.org/10.1111/j.1365-2265.1992.tb00956.x.

  32. Barrios-Ospino Y, Díaz N, Meertens L, NaddafG, Solano L, Fernández M, et al. [Relation betweenleptin serun with weight and body fat distributionin postmenopausal women]. Nutr Hosp2010;25:80-84.

  33. Braunstein GD. Aromatase and gynecomastia.Endocr Relat Cancer 1999;6:315-324. https://doi.org/10.1677/erc.0.0060315.

  34. Stanworth R, Jones T. Testosterone in obesity,metabolic syndrome and type 2 diabetes.Front Horm Res 2009;37:74-90. https://doi.org/10.1159/000176046.

  35. Barros AC, Sampaio MdC. Gynecomastia: physiopathology,evaluation and treatment. SaoPaulo Med J 2012;130:187-197.

  36. Hershkovitz E, Leiberman E. Gynecomastia:A review. Endocrinologist 2002;12:321-332.https://doi.org/10.1097/00019616-200207000-00010.

  37. Carlson HE. Approach to the patient with gynecomastia.J Clin Endocrinol Metab 2011;96:15-21. https://doi.org/10.1210/jcem.96.9.zeg15a.

  38. Magro G, Gangemi P, Villari L, Greco P. Deciduoid-like stromal cells in a diabetic patient withbilateral gynecomastia: a potential diagnosticpitfall. Virchows Archiv 2004;445:659-660.

  39. Pearlman G, Carlson HE. Gynecomastia: Anupdate. Endocrinologist 2006;16:109-115.https://doi.org/10.1097/01.ten.0000205637.20746.10.

  40. García-Benayas T, Blanco F, Martín-Carbonero L, Valencia E, Barrios A,González-Lahoz J, et al. Gynecomastiain HIV-Infected patients receiving antiretroviraltherapy. AIDS Res Hum Retroviruses2003;19:739-741. https://doi.org/10.1089/088922203769232539.

  41. Krause W. Drug-inducing gynaecomastia--a critical review. Andrologia 2012;44 Suppl1:621-626. https://doi.org/10.1111/j.1439-0272.2011.01240.x.

  42. Holzbeierlein JM. Managing complicationsof androgen deprivation therapy for prostatecancer. Urol Clin North Am 2006;33:181-190.https://doi.org/10.1016/j.ucl.2005.12.008.

  43. Manolis AA, Manolis TA, Melita H, ManolisAS. Spotlight on spironolactone oral suspensionfor the treatment of heart failure: Focuson patient selection and perspectives. VascHealth Risk Manag 2019;15:571-579. https://doi.org/10.2147/VHRM.S210150.

  44. Skeldon SC, Carleton B, Brophy JM, SodhiM, Etminan M. Statin medications andthe risk of gynecomastia. Clin Endocrinol2018;89:470-473. https://doi.org/https://doi.org/10.1111/cen.13794.

  45. Dickson G. Gynecomastia. Am Fam Physician2012;85:716-722.

  46. Basaria S. Androgen abuse in athletes: detectionand consequences. J Clin EndocrinolMetab 2010;95:1533-1543. https://doi.org/10.1210/jc.2009-1579.

  47. Rouach H, Fataccioli V, Gentil M, FrenchSW, Morimoto M, Nordmann R. Effect ofchronic ethanol feeding on lipid peroxidationand protein oxidation in relation to liverpathology. Hepatology 1997;25:351-355.https://doi.org/10.1002/hep.510250216.

  48. Sauer MA, Rifka SM, Hawks RL, Cutler GB,Jr., Loriaux DL. Marijuana: interaction withthe estrogen receptor. J Pharmacol Exp Ther1983;224:404-407.

  49. Dursun F, Su Dur ŞM, Şahin C, KırmızıbekmezH, Karabulut MH, Yörük A. A rare cause ofprepubertal gynecomastia: Sertoli cell tumor.Case Rep Pediatr 2015;2015:439239. https://doi.org/10.1155/2015/439239.

  50. Chentli F, Bekkaye I, Azzoug S. Feminizingadrenocortical tumors: Literature review. Indian J Endocrinol Metab 2015;19:332-339.https://doi.org/10.4103/2230-8210.152764.

  51. Brinton LA. Breast cancer risk among patientswith Klinefelter syndrome. Acta Paediatr2011;100:814-818. https://doi.org/10.1111/j.1651-2227.2010.02131.x.

  52. Ersöz H, Onde ME, Terekeci H, Kurtoglu S, TorH. Causes of gynaecomastia in young adult malesand factors associated with idiopathic gynaecomastia.Int J Androl 2002;25:312-316. https://doi.org/10.1046/j.1365-2605.2002.00374.x.

  53. Sarıca Ö, Kahraman AN, Öztürk E, Teke M.Efficiency of imaging modalities in male breastdisease: Can ultrasound give additional informationfor assessment of gynecomastiaevolution? Eur J Breast Health 2018;14:29-34.https://doi.org/10.5152/ejbh.2017.3416.

  54. Simon BE, Hoffman S, Kahn S. Classificationand surgical correction of gynecomastia. PlastReconstr Surg 1973;51:48-52. https://doi.org/10.1097/00006534-197301000-00009.

  55. Nordt CA, DiVasta AD. Gynecomastiain adolescents. Curr Opin Pediatr2008;20:375-382. https://doi.org/10.1097/MOP.0b013e328306a07c.

  56. Nuttall FQ. Gynecomastia. Mayo Clin Proc2010;85:961-962. https://doi.org/10.4065/mcp.2010.0093.

  57. Martínez-Tlahuel JL, Arce C, Lara FU. Cáncerde mama en el hombre. Cancerología2006;1:201-210.

  58. Hines SL, Tan WW, Yasrebi M, DePeri ER,Perez EA. The role of mammography inmale patients with breast symptoms. MayoClin Proc 2007;82:297-300. https://doi.org/10.4065/82.3.297.

  59. Mayo Clinic. Enlarged breasts in men (gynecomastia).Minnesota, USA: Mayo Foundation forMedical Education and Research; 2019. Acceso08 de julio de 2020. Disponible en https://www.mayoclinic.org/diseases-conditions/gynecomastia/diagnosis-treatment/drc-20351799.

  60. Cuhaci N, Polat SB, Evranos B, Ersoy R,Cakir B. Gynecomastia: Clinical evaluationand management. Indian J EndocrinolMetab 2014;18:150-158. https://doi.org/10.4103/2230-8210.129104.

  61. Mannu GS, Sudul M, Bettencourt-Silva JH,Tsoti SM, Cunnick G, Ahmed SF. Role of tamoxifenin idiopathic gynecomastia: A 10-year prospectivecohort study. Breast J 2018;24:1043-1045. https://doi.org/10.1111/tbj.13080.

  62. Ting AC, Chow LW, Leung YF. Comparison of tamoxifenwith danazol in the management of idiopathicgynecomastia. Am Surg 2000;66:38-40.

  63. Lapid O, van Wingerden JJ, Perlemuter L. Tamoxifentherapy for the management of pubertalgynecomastia: a systematic review. J PediatrEndocrinol Metab 2013;26:803-807. https://doi.org/10.1515/jpem-2013-0052.

  64. Gikas P, Mokbel K. Management of gynaecomastia:an update. Int J Clin Pract2007;61:1209-1215. https://doi.org/10.1111/j.1742-1241.2006.01095.x.

  65. Plourde PV, Reiter EO, Jou HC, DesrochersPE, Rubin SD, Bercu BB, et al. Safety andefficacy of anastrozole for the treatment of pubertalgynecomastia: a randomized, doubleblind,placebo-controlled trial. J Clin EndocrinolMetab 2004;89:4428-4433. https://doi.org/10.1210/jc.2004-0082.

  66. Boccardo F, Rubagotti A, Battaglia M, Di TonnoP, Selvaggi FP, Conti G, et al. Evaluation oftamoxifen and anastrozole in the preventionof gynecomastia and breast pain induced bybicalutamide monotherapy of prostate cancer.J Clin Oncol 2005;23:808-815. https://doi.org/10.1200/jco.2005.12.013.

  67. Ferraro GA, De Francesco F, Romano T, GrandoneA, D'Andrea F, Miraglia Del GiudiceE, et al. Clinical and surgical managementof unilateral prepubertal gynecomastia. Int JSurg Case Rep 2014;5:1158-1161. https://doi.org/10.1016/j.ijscr.2014.11.040.




2020     |     www.medigraphic.com